Meridian Crescent Partners III, L.P.
Quarterly Report to Limited Partners — Second Quarter 2026
Prepared by
Meridian Crescent Partners
As of June 30, 2026 · Issued July 24, 2026
Confidential
Prepared by
Meridian Crescent Partners
As of June 30, 2026 · Issued July 24, 2026
Confidential
Dear Limited Partners,
Fund III ended the quarter at a net TVPI of 1.43x, a DPI of 0.31x, and an 18.4% net IRR. Those figures are consistent with the fund we described when we asked for your capital. We are pleased with the quarter; we will spend this letter on the part of it that was not pleasing.
The markdown. We reduced Tern Labs by $17.8 million, to 0.72x cost — the fund's first material markdown. AI-native alternatives have compressed exactly the budget line Tern sells into, and net revenue retention has now spent two quarters below 100%. Our underwriting error was durability: we paid a price that assumed Tern's growth was structural, and some of it was demand pulled forward. The company has cash into 2028 and a credible rebuild plan, but the mark reflects the business as it is, not the plan as we hope it unfolds. We would rather report a fair number today than a flattering one we walk back later.
The realization. We sold roughly 15% of our Arcadine position for $28.4 million — 7.9% above our March 31 carrying value, a useful external check on our marks — and distributed the proceeds in full. We sold because the price was full and the position had grown to nearly a quarter of NAV, not because conviction changed; Arcadine grew ARR 35% year over year.
Deployment stays deliberate: 72% called, $238 million of dry powder, and a pipeline we are underwriting to 2023–24 entry discipline. We thank you for your partnership — the annual meeting is October 14 in New York, and we welcome your questions before then.
Respectfully,
Thomas Ainsley · Ruth Calder — Managing Partners
NAV first exceeded called capital in the fund's seventh quarter. Q2 markdowns were concentrated in Tern Labs ($17.8 of the $21.9).
Eleven active companies: $500.0 cost, $743.8 fair value — 1.49x gross.
| Company | Sector | Initial inv. | Cost ($M) | Fair value ($M) | Gross MOIC |
|---|---|---|---|---|---|
| Arcadine Systems | Supply-chain software | Oct 2022 | 68.0 | 142.7 | 2.10x |
| Veritline Health | Healthcare data | Dec 2022 | 40.8 | 89.4 | 2.19x |
| Cobalt Ridge Software | Field-service software | Mar 2023 | 54.2 | 96.6 | 1.78x |
| Helm & Harbor | Logistics software | Jun 2023 | 48.7 | 68.3 | 1.40x |
| Quillstone | Legal workflow | Sep 2023 | 45.0 | 66.4 | 1.48x |
| Basalt Peak Analytics | Industrial analytics | Jan 2024 | 52.6 | 78.1 | 1.48x |
| Fairwater Compliance | Compliance software | Apr 2024 | 41.8 | 52.3 | 1.25x |
| Tern Labs | Developer tooling | Aug 2024 | 38.5 | 27.7 | 0.72x |
| Rushmore Payments | Vertical payments | Nov 2024 | 44.3 | 51.9 | 1.17x |
| Lantern Grid | Utility software | Feb 2025 | 36.1 | 39.0 | 1.08x |
| Pinebrook Data | Data-infra services | May 2025 | 30.0 | 31.4 | 1.05x |
| Total — active portfolio | 500.0 | 743.8 | 1.49x |
The five largest positions are 64% of portfolio fair value; Arcadine Systems is 20.8% of NAV after the June partial sale. One position is carried below cost (Tern Labs, 0.72x). Every mark this quarter moved on trailing performance, not rerating.
Order-orchestration software for mid-market distributors and 3PLs. ARR of $71.3 million, up 35% year over year; 118% net revenue retention; EBITDA break-even.
Sold ~15% of the position in June for $28.4 million (7.9% above prior marks) and distributed the proceeds. Remaining position: $142.7 million, 2.10x cost — the fund's largest.
$612.0 called across eight calls; $189.7 distributed across six; $238.0 unfunded. Call No. 9 expected late in Q3 2026 (est. $35–40), plus the H2 management fee.
| Quarter ended Jun 30, 2026 | Inception to date | |
|---|---|---|
| Partners' capital, beginning of period | 658.4 | — |
| Contributions | 30.0 | 612.0 |
| Distributions | (28.4) | (189.7) |
| Realized gains on investments | 16.4 | 100.5 |
| Dividend and interest income | 0.8 | 44.1 |
| Management fees and partnership expenses | (4.1) | (59.4) |
| Net change in unrealized appreciation | 18.8 | 243.8 |
| Carried interest allocated to the General Partner | (6.4) | (65.8) |
| Partners' capital, end of period | 685.5 | 685.5 |